1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2020, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.
Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 7, 7, 1, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionCancer Pain - Overview
Cancer Pain - Therapeutics Development
Cancer Pain - Therapeutics Assessment
Cancer Pain - Companies Involved in Therapeutics Development
Cancer Pain - Drug Profiles
Cancer Pain - Dormant Projects
Cancer Pain - Discontinued Products
Cancer Pain - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Cancer Pain, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2020
- Cancer Pain - Pipeline by AngioChem Inc, H2 2020
- Cancer Pain - Pipeline by Aphios Corp, H2 2020
- Cancer Pain - Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
- Cancer Pain - Pipeline by AstraZeneca Plc, H2 2020
- Cancer Pain - Pipeline by Beckley Canopy Therapeutics Ltd, H2 2020
- Cancer Pain - Pipeline by Cassava Sciences Inc, H2 2020
- Cancer Pain - Pipeline by Concentric Analgesics Inc, H2 2020
- Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2020
- Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2020
- Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2020
- Cancer Pain - Pipeline by Intec Pharma Ltd, H2 2020
- Cancer Pain - Pipeline by IntelGenx Corp, H2 2020
- Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2020
- Cancer Pain - Pipeline by Jiangsu Huatai Chenguang Pharmaceutical Co Ltd, H2 2020
- Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2020
- Cancer Pain - Dormant Projects, H2 2020
- Cancer Pain - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Cancer Pain, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexza Pharmaceuticals Inc
- AngioChem Inc
- Aphios Corp
- Aquilus Pharmaceuticals Inc
- AstraZeneca Plc
- Beckley Canopy Therapeutics Ltd
- Cassava Sciences Inc
- Concentric Analgesics Inc
- Dompe Farmaceutici SpA
- Fujimoto Pharmaceutical Corp
- Hisamitsu Pharmaceutical Co Inc
- Intec Pharma Ltd
- IntelGenx Corp
- iX Biopharma Ltd
- Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
- Klaria Pharma Holding AB
- Komipharm International Co Ltd
- Luye Pharma Group Ltd
- Medlab Clinical Ltd
- Mundipharma International Ltd
- Nanomerics Ltd
- Neurocentrx Pharma Ltd
- Nippon Zoki Pharmaceutical Co Ltd
- Orion Corp
- Park Therapeutics Inc
- Pfizer Inc
- Pharmaleads SA
- ProNeurogen Inc
- Ribomic Inc
- Sedor Pharmaceuticals LLC
- Sorrento Therapeutics Inc
- Tetra Bio-Pharma Inc
- WEX Pharmaceuticals Inc
- Winston Pharmaceuticals Inc
- Yichang Renfu Pharmaceutical Co Ltd
- Yongzhan International Pharmaceutical Co Ltd
